Increasing time to treatment initiation for head and neck cancer: An analysis of the National Cancer Database

Cancer

Volumn 121, Issue 8, 2015, Pages 1204-1213

  Murphy, Colin T ^a   Galloway, Thomas J ^a   Handorf, Elizabeth A ^a   Wang, Lora ^a   Mehra, Ranee ^a   Flieder, Douglas B ^a   Ridge, John A ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

facility type; head and neck cancer; National Cancer Database; One more; treatment time

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CHEMORADIOTHERAPY; DATA BASE; EDUCATIONAL STATUS; ETHNICITY; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEALTH INSURANCE; HUMAN; HYPOPHARYNX CANCER; LARYNX CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OROPHARYNX CANCER; PRIORITY JOURNAL; RACE; TIME TO TREATMENT; TONGUE CANCER; TREND STUDY; UNIVERSITY HOSPITAL; CANCER CENTER; CARCINOMA, SQUAMOUS CELL; FACTUAL DATABASE; HEAD AND NECK NEOPLASMS; MULTIVARIATE ANALYSIS; NONPARAMETRIC TEST; ORGANIZATION AND MANAGEMENT; PATHOLOGY; STATISTICS AND NUMERICAL DATA; TRENDS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CANCER CARE FACILITIES; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; DATABASES, FACTUAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; STATISTICS, NONPARAMETRIC; TIME-TO-TREATMENT;

EID: 84927108399     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29191     Document Type: Article

References (42)

1. Bourhis J, Overgaard J, Audry H, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet. 2006; 368: 843-854.
2. Beitler JJ, Zhang Q, Fu KK, et al. Final results of local-regional control and late toxicity of RTOG 9003: a randomized trial of altered fractionation radiation for locally advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 2014; 89: 13-20.
3. Overgaard J, Hansen HS, Specht L, et al. Five compared with 6 fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet. 2003; 362: 933-940.
4. Ang KK, Trotti A, Brown BW, et al. Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001; 51: 571-578.
5. Fortin A, Bairati I, Albert M, Moore L, Allard J, Couture C,. Effect of treatment delay on outcome of patients with early-stage head-and-neck carcinoma receiving radical radiotherapy. Int J Radiat Oncol Biol Phys. 2002; 52: 929-936.
6. Hansen O, Larsen S, Bastholt L, Godballe C, Jørgensen KE,. Duration of symptoms: impact on outcome of radiotherapy in glottic cancer patients. Int J Radiat Oncol Biol Phys. 2005; 61: 789-794.
7. Chen Z, King W, Pearcey R, Kerba M, Mackillop WJ,. The relationship between waiting time for radiotherapy and clinical outcomes: a systematic review of the literature. Radiother Oncol. 2008; 87: 3-16.
8. Mackillop WJ, Bates JH, O'Sullivan B, Withers HR,. The effect of delay in treatment on local control by radiotherapy. Int J Radiat Oncol Biol Phys. 1996; 34: 243-250.
9. Jensen AR, Nellemann HM, Overgaard J,. Tumor progression in waiting time for radiotherapy in head and neck cancer. Radiother Oncol. 2007; 84: 5-10.
10. Robinson KM, Christensen KB, Ottesen B, Krasnik A,. Diagnostic delay, quality of life and patient satisfaction among women diagnosed with endometrial or ovarian cancer: a nationwide Danish study. Qual Life Res. 2012; 21: 1519-1525.
11. Haisfield-Wolfe ME, McGuire DB, Soeken K, Geiger-Brown J, De Forge BR,. Prevalence and correlates of depression among patients with head and neck cancer: a systematic review of implications for research. Oncol Nurs Forum. 2009; 36: E107-E125.
12. Hess CB, Chen AM,. Measuring psychosocial functioning in the radiation oncology clinic: a systematic review. Psychooncology. 2014; 23: 841-854.
13. Bilimoria KY, Stewart AK, Winchester DP, Ko CY,. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008; 15: 683-690.
14. National Cancer Data Base. Diagnostic Confirmation. Available at: http://ncdbpuf.facs.org/?q=content/diagnostic-confirmation. Accessed November 6, 2014.
15. Vuong QH,. Likelihood ratio tests for model selection and non-nested hypotheses. Econometrica. 1989; 57: 307-333.
16. Bietendorf J,. FDG PET reimbursement. J Nucl Med Technol. 2004; 32: 33-38.
17. Lonneux M, Hamoir M, Reychler H, et al. Positron emission tomography with [18F]fluorodeoxyglucose improves staging and patient management in patients with head and neck squamous cell carcinoma: a multicenter prospective study. J Clin Oncol. 2010; 28: 1190-1195.
18. Hillner BE, Tosteson AN, Song Y, et al. Growth in the use of PET for 6 cancer types after coverage by Medicare: additive or replacement? J Am Coll Radiol. 2012; 9: 33-41.
19. Dinan MA, Curtis LH, Hammill BG, et al. Changes in the use and costs of diagnostic imaging among Medicare beneficiaries with cancer, 1999-2006. JAMA. 2010; 303: 1625-1631.
20. Bleicher RJ, Ruth K, Sigurdson ER, et al. Preoperative delays in the US Medicare population with breast cancer. J Clin Oncol. 2012; 30: 4485-4492.
21. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011; 29: 4294-4301.
22. Mell LK, Mehrotra AK, Mundt AJ,. Intensity-modulated radiation therapy use in the United States, 2004. Cancer. 2005; 104: 1296-1303.
23. Nutting CM, Morden JP, Harrington KJ, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2011; 12: 127-136.
24. Yong JHE, Beca J, O'Sullivan B, et al. Cost-effectiveness of intensity-modulated radiotherapy in oropharyngeal cancer. Clin Oncol (R Coll Radiol). 2012; 24: 532-538.
25. Guadagnolo BA, Liu C-C, Cormier JN, Du XL,. Evaluation of trends in the use of intensity-modulated radiotherapy for head and neck cancer from 2000 through 2005: socioeconomic disparity and geographic variation in a large population-based cohort. Cancer. 2010; 116: 3505-3512.
26. Sher DJ, Neville BA, Chen AB, Schrag D,. Predictors of IMRT and conformal radiotherapy use in head and neck squamous cell carcinoma: a SEER-Medicare analysis. Int J Radiat Oncol Biol Phys. 2011; 81: e197-e206.
27. Ezzell GA, Galvin JM, Low D, et al. Guidance document on delivery, treatment planning, and clinical implementation of IMRT: report of the IMRT Subcommittee of the AAPM Radiation Therapy Committee. Med Phys. 2003; 30: 2089-2115.
28. Garden AS,. The never-ending story: finding a role for neoadjuvant chemotherapy in the management of head and neck cancer. J Clin Oncol. 2014; 32: 2685-2686.
29. Pignon JP, Bourhis J, Domenge C, Designé L,. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: 3 meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000; 355: 949-955.
30. Pfister DG, Ang K-K, Brizel DM, et al. Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines. J Natl Compr Cancer Netw. 2013; 11: 917-923.
31. Wallace CG, Chang Y-M, Tsai C-Y, Wei F-C,. Harnessing the potential of the free fibula osteoseptocutaneous flap in mandible reconstruction. Plast Reconstr Surg. 2010; 125: 305-314.
32. Toto JM, Chang EI, Agag R, Devarajan K, Patel SA, Topham NS,. Improved operative efficiency of free fibula flap mandible reconstruction with patient-specific, computer-guided preoperative planning [published online ahead of print June 21, 2014]. Head Neck. 2014.
33. Adelstein DJ, Ridge JA, Brizel DM, et al. Transoral resection of pharyngeal cancer: summary of a National Cancer Institute Head and Neck Cancer Steering Committee Clinical Trials Planning Meeting, November 6-7, 2011, Arlington, Virginia. Head Neck. 2012; 34: 1681-1703.
34. Yu X, Lum D, Kiet TK, et al. Utilization of and charges for robotic versus laparoscopic versus open surgery for endometrial cancer. J Surg Oncol. 2013; 107: 653-658.
35. Barbash GI, Friedman B, Glied SA, Steiner CA,. Factors associated with adoption of robotic surgical technology in US hospitals and relationship to radical prostatectomy procedure volume. Ann Surg. 2014; 259: 1-6.
36. Neuner JM, See WA, Pezzin LE, Tarima S, Nattinger AB,. The association of robotic surgical technology and hospital prostatectomy volumes: increasing market share through the adoption of technology. Cancer. 2012; 118: 371-377.
37. Stitzenberg KB, Wong Y-N, Nielsen ME, Egleston BL, Uzzo RG,. Trends in radical prostatectomy: centralization, robotics, and access to urologic cancer care. Cancer. 2012; 118: 54-62.
38. Albano JD, Ward E, Jemal A, et al. Cancer mortality in the United States by education level and race. J Natl Cancer Inst. 2007; 99: 1384-1394.
39. Shavers VL, Harlan LC, Winn D, Davis WW,. Racial/ethnic patterns of care for cancers of the oral cavity, pharynx, larynx, sinuses, and salivary glands. Cancer Metastasis Rev. 2003; 22: 25-38.
40. Ward E, Jemal A, Cokkinides V, et al. Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin. 2004; 54: 78-93.
41. Brouha XD, Op De Coul B, Terhaard CH, Hordijk GJ,. Does waiting time for radiotherapy affect local control of T1N0M0 glottic laryngeal carcinoma? Clin Otolaryngol Allied Sci. 2000; 25: 215-218.
42. Leõn X, de Vega M, Orús C, Morán J, Vergés J, Quer M,. The effect of waiting time on local control and survival in head and neck carcinoma patients treated with radiotherapy. Radiother Oncol. 2003; 66: 277-281.